CereMark Pharma

Who We Are

CereMark Pharma™ LLC, a West Virginia limited liability corporation, was formed in 2013 by a group of physicians, scientists and attorneys with recognized expertise and distinguished careers in research and support of individuals who have experienced traumatic brain injury, or Alzheimer’s disease or both. The mission of CereMark Pharma™ is to license and develop new molecules as investigational new drugs to enable better diagnosis and treatment of tau- and amyloid-linked pathologies of the brain resulting from either disease or traumatic brain injury. CereMark Pharma™ LLC has licensed all rights to F-18 Flornaptitril (fka, F-18 FDDNP) from UCLA, where researchers created and first reported research findings on F-18 Flornaptitril’s ability to provide tau- and amyloid-related PET images of living subjects with Alzheimer’s disease and suspected CTE. F-18 Flornaptitril is an investigational new drug limited to research pursuant to FDA guidelines and restrictions.

Henry M. Chilton, Pharm. D., MBA

Chief Executive Officer

Bennet Omalu, M.D., C.P.E., M.B.A., M.P.H.

Board Member, Founder

James “Bus” Cook, Jr.

Board Member, Founder

Robert P. Fitzsimmons, J.D.

Managing Director, Chairman and Founder

Billy L. West, Jr., J.D.

Board Member, Founder

Jorge R. Barrio, Ph.D.

Board Member, Founder

William C. (Trey) Putnam, III, Ph.D.

Chief Regulatory and Science Officer

Gary Small, M.D.

Board Member, Founder

Julian E. Bailes, M.D.

Chief Medical Officer, Chairman MSAB

Dr. John “Jack” Lee


Donna Cross, PhD.


Satoshi Minoshima, M.D., Ph.D.


Edward D. Hall, Ph.D.


be part of our success. Learn More.